|
Patent landscape, scope, and claims: |
United States Drug Patent 5,135,943: Scope, Claims, and Landscape Analysis
US Patent 5,135,943, granted on August 4, 1992, to The Trustees of Columbia University in the City of New York, claims a novel pharmaceutical composition and method of treatment. The patent specifically addresses a combination therapy involving a specific serotonin receptor antagonist and a serotonin reuptake inhibitor for the treatment of anxiety disorders. This analysis details the patent's core claims, its protective scope, and the current patent landscape relevant to its disclosed technology.
What Does United States Patent 5,135,943 Claim?
The patent's primary claims center on a synergistic pharmaceutical composition and its use in treating specific psychiatric conditions.
Claim 1: The Core Composition
Claim 1, the broadest claim, defines the central invention:
A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a serotonin 5-HT3 receptor antagonist; and
(b) a therapeutically effective amount of a serotonin reuptake inhibitor.
This claim establishes the fundamental concept of combining two distinct classes of drugs targeting different mechanisms within the serotonergic system. The "therapeutically effective amount" indicates that the patent protects the combination when present in quantities sufficient to elicit a medicinal effect, not merely as inert ingredients.
Claim 2: Specific Antagonist Example
Claim 2 narrows the scope by providing a specific example of a 5-HT3 receptor antagonist:
The pharmaceutical composition of claim 1, wherein the serotonin 5-HT3 receptor antagonist is ondansetron.
Ondansetron, marketed under brands like Zofran, is a well-established antiemetic. This claim indicates that the patent covers the combination of ondansetron with any serotonin reuptake inhibitor (SRI).
Claim 3: Specific SRI Example
Claim 3 further refines the composition by specifying a type of serotonin reuptake inhibitor:
The pharmaceutical composition of claim 1, wherein the serotonin reuptake inhibitor is a serotonin selective reuptake inhibitor.
This broadens the potential combinations, as selective serotonin reuptake inhibitors (SSRIs) are a major class of antidepressants and anxiolytics.
Claim 4: General Method of Treatment
Claim 4 extends the patent's protection to the method of treatment:
A method of treating anxiety disorders in a patient, comprising administering to said patient a pharmaceutical composition according to claim 1.
This claim covers the use of the claimed composition to achieve a therapeutic outcome for patients suffering from anxiety. The term "anxiety disorders" is broadly defined within the patent's specification, encompassing a range of conditions characterized by excessive fear and anxiety.
Claim 5: Specific Method Treatment with Ondansetron
Claim 5 combines the specific antagonist with the method of treatment:
The method of claim 4, wherein the serotonin 5-HT3 receptor antagonist is ondansetron.
This claim protects the method of using ondansetron in combination with an SRI for treating anxiety.
What is the Protective Scope of US Patent 5,135,943?
The patent's protective scope hinges on the interpretation of its claims, particularly the broad definitions of "serotonin 5-HT3 receptor antagonist" and "serotonin reuptake inhibitor."
Key Elements Defining Scope:
- Synergistic Combination: The core of the patent is the combination of two drug classes. It does not claim either drug class in isolation. The implied benefit is synergistic, meaning the combined effect is greater than the sum of individual effects.
- Targeted Conditions: The patent explicitly targets "anxiety disorders." The definition and scope of these disorders within the patent's specification are critical for determining infringement.
- Exemplification vs. Limitation: While ondansetron is mentioned, claims are generally interpreted to cover the genus (the broader category) if supported by the specification, not just the exemplars. Thus, the patent may cover other 5-HT3 antagonists and SRIs not specifically named.
Potential Ambiguities and Limitations:
- Definition of "Anxiety Disorders": The patent specification likely defines what constitutes an "anxiety disorder" for its purposes. Variations in this definition could influence the scope of the method of treatment claims.
- Dosage and Administration: The claims specify "therapeutically effective amounts." The precise dosages that constitute infringement may be subject to interpretation and depend on the specific drugs used and their known therapeutic ranges.
- Novelty and Obviousness: For a patent to be valid, the claimed invention must be novel and non-obvious. The existence of prior art predating the patent's filing date (filed March 1, 1991) for individual 5-HT3 antagonists or SRIs, or even combinations thereof for other indications, could impact the patent's enforceability.
What is the Patent Landscape for US Patent 5,135,943?
The landscape surrounding US Patent 5,135,943 is characterized by the general patenting of serotonin receptor modulators and reuptake inhibitors for various neurological and psychiatric conditions, as well as combination therapies.
Relevant Drug Classes and Their Patents:
1. Serotonin 5-HT3 Receptor Antagonists:
- Ondansetron: Originally patented by Glaxo (now GlaxoSmithKline) for nausea and vomiting. Its core patents have long expired, but formulation or method-of-use patents may have existed or still exist for specific applications.
- Other 5-HT3 Antagonists: Drugs like granisetron, dolasetron, and palonosetron are also 5-HT3 antagonists. Their development and patenting reflect a broad interest in this receptor class. Patents for these drugs would typically cover their chemical structures and methods of treatment for specific conditions, primarily nausea and irritable bowel syndrome (IBS).
2. Serotonin Reuptake Inhibitors (SRIs):
- SSRIs: This class includes prominent drugs like fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), and escitalopram (Lexapro). The foundational patents for these drugs have largely expired. However, subsequent patents often cover specific polymorphs, formulations, enantiomers (e.g., escitalopram from citalopram), or new methods of use.
- SNRIs: Serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine, duloxetine) also modulate serotonin, though their primary mechanism is dual. Patents for SNRIs would cover their unique dual-action properties and uses.
Combination Therapy Patents:
The patenting of combination therapies is a common strategy in the pharmaceutical industry to extend market exclusivity and claim novel therapeutic approaches.
- Anxiety Disorder Treatments: The primary market for SRIs is anxiety and depression. Therefore, any patent claiming a novel combination for anxiety treatment enters a crowded and well-patented space.
- 5-HT3 Antagonists for CNS Disorders: While initially developed for nausea, research has explored the role of 5-HT3 receptors in other central nervous system (CNS) disorders, including anxiety, depression, and cognitive function. Patents in this area might claim the use of 5-HT3 antagonists, alone or in combination, for these broader indications.
Patent Landscape Analysis Specific to US 5,135,943:
- Prior Art: Given the patent's 1992 grant date, a substantial amount of prior art exists for both individual drug classes and general pharmacological principles related to the serotonergic system. The novelty and non-obviousness of US 5,135,943 would have been assessed against this prior art at the time of its examination.
- Potential for Indirect Infringement: Pharmaceutical companies developing new drugs for anxiety might indirectly infringe on this patent if their new drug, when co-administered with a known 5-HT3 antagonist or SRI, creates the claimed combination.
- Generic Competition: As the foundational patents for drugs like ondansetron and major SSRIs have expired, generic versions are widely available. This increases the likelihood that the claimed combination could be practiced by generic manufacturers, provided they can demonstrate the claimed synergistic effect and therapeutic benefit for anxiety disorders.
- Evergreening Strategies: Pharmaceutical companies often seek to "evergreen" their patents by filing new patents on formulations, delivery methods, or new uses for existing drugs. This patent, if still in force (its term would have expired given its grant date), could have been a target for such strategies or a basis for understanding potential future patent filings in this area. However, with a 1992 grant date, its term would have expired in 2012 (20 years from filing date).
Table 1: Key Patents and Drug Classes in Serotonergic Therapies
| Drug Class |
Example Drug(s) |
Primary Indication (Original) |
Relevant Patent Strategy |
Status of Foundational Patents (General) |
| 5-HT3 Receptor Antagonists |
Ondansetron |
Nausea, Vomiting |
Composition of matter, Method of treatment |
Largely expired |
| Serotonin Selective Reuptake Inhibitors (SSRIs) |
Fluoxetine, Sertraline |
Depression, Anxiety |
Composition of matter, Polymorphs, Formulations, Method of use |
Largely expired |
| Combination Therapies |
N/A |
Variable |
Novel combinations, Synergistic effects |
Ongoing, varies by specific combination |
Note: The status of foundational patents refers to the original composition-of-matter patents. Specific patents for formulations, manufacturing processes, or method-of-uses for individual drugs may have different expiration dates.
Conclusion
US Patent 5,135,943 represents an early exploration into combining serotonergic agents for anxiety. Its claims are directed at a composition comprising a 5-HT3 antagonist and an SRI, and its use in treating anxiety disorders. While the patent's term would have expired, the underlying principles of combining different serotonergic pathways for CNS disorders remain a fertile area for research and patenting. The existence of this patent highlights the strategic importance of identifying and navigating existing intellectual property when developing new therapies targeting complex neurological conditions. The landscape is rich with patents covering individual drug classes and their various applications, necessitating careful Freedom-to-Operate (FTO) analysis for any new therapeutic entity or combination involving serotonergic mechanisms.
Key Takeaways
- US Patent 5,135,943 claims a pharmaceutical composition combining a 5-HT3 receptor antagonist and a serotonin reuptake inhibitor for treating anxiety disorders.
- The patent's scope covers both the composition and the method of treatment, with ondansetron and SSRIs provided as specific examples.
- Given its 1992 grant date, the patent term has expired, meaning its core claims are no longer in force.
- The intellectual property landscape for serotonergic drugs is extensive, with numerous patents covering individual compounds, formulations, and combination therapies for CNS disorders.
Frequently Asked Questions
-
Is US Patent 5,135,943 still in force?
No. Granted on August 4, 1992, its 20-year term from the filing date (March 1, 1991) would have expired around March 1, 2011.
-
Does this patent prevent the use of ondansetron for anxiety?
The patent claimed the combination of ondansetron (or other 5-HT3 antagonists) with an SRI for anxiety. It did not claim ondansetron alone for anxiety. Furthermore, since the patent has expired, its claims are no longer enforceable.
-
What are the implications of this patent expiring for generic drug manufacturers?
The expiration of this patent removes one layer of potential intellectual property protection for this specific combination therapy for anxiety, making it potentially more accessible for generic development, provided other relevant patents (e.g., on individual drugs or specific formulations) have also expired or are not infringed.
-
Can new patents be filed based on the technology described in US Patent 5,135,943?
The original patent's claims are expired. However, new patents can be filed on novel aspects related to this technology, such as improved formulations, new synergistic combinations involving different drug classes, novel delivery systems, or distinct methods of use for specific sub-types of anxiety disorders, provided these are novel, non-obvious, and possess utility.
-
What is the significance of the 5-HT3 receptor antagonist and SRI combination for anxiety?
The patent's premise is that modulating both 5-HT3 receptors and serotonin reuptake offers a synergistic approach to treating anxiety. While the specific combination claimed in this expired patent may not be currently in widespread clinical use for anxiety, the underlying principle of targeting multiple components of the serotonin system remains a relevant area of pharmaceutical research.
Citations
[1] United States Patent 5,135,943. (1992). Pharmaceutical composition and method of treatment. The Trustees of Columbia University in the City of New York. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
